Динаміка рівнів імунозапальних маркерів на тлі терапії кверцетином у хворих на ішемічну хворобу серця, асоційовану з гіпотиреозом
DOI :
https://doi.org/10.15587/2313-8416.2016.59038Mots-clés :
імунозапальні маркери, ішемічна хвороба серця, гіпотиреоз, кверцетинRésumé
Досліджено динаміку рівнів імунозапальних маркерів у хворих на ішемічну хворобу серця, асоційовану з гіпотиреозом, на тлі терапії кверцетином. Встановлено, що кверцетин у комплексному лікуванні хворих на ішемічну хворобу серця з супутнім гіпотиреозом впродовж 3 місяців поліпшує функціональний стан ендотелію та знижує активацію системного запального процесу
Références
Mitchenko, O., Lohvynenko, A., Romanov, V. (2010). Optymizatsiya likuvannya dyslipidemiy ta porushen' vuhlevodnoho obminiv u khvorykh z metabolichnym syndromom ta dysfunktsiyeyu shchytopodibnoyi zalozy [Optimization of treatment of dyslipidemia and disorders of carbohydrate metabolism in patients with metabolic syndrome and thyroid dysfunction]. Ukrainian Journal of Cardiology, 1, 73–80.
Tseng, F.-Y., Lin, W.-Y., Lin, C.-C., Lee, L.-T., Li, T.-C., Sung, P.-K., Huang, K.-C. (2012). Subclinical Hypothyroidism Is Associated With Increased Risk for All-Cause and Cardiovascular Mortality in Adults. Journal of the American College of Cardiology, 60 (8), 730–737. doi: 10.1016/j.jacc.2012.03.047
D’Alessandris, C., Lauro, R., Presta, I., Sesti, G. (2007). C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia, 50 (4), 840–849. doi: 10.1007/s00125-006-0522-y
Dal Lin, C., Tona, F., Osto, E. (2015). Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters. International Journal of Endocrinology, 2015, 1–17. doi: 10.1155/2015/312848
Kostoglou-Athanassiou, I., Ntalles, K. (2010). Hypothyroidism – new aspects of an old disease. Hippokratia, 14 (2), 82–87.
Ayers, S., Webb, P. (2014). Thyroid hormone analogues: their role in treatment of hyperlipidemia. Journal of Endocrinology, Diabetes & Obesity, 2 (3), 1042. Available at: http://www.jscimedcentral.com/Endocrinology/endocrinology-spid-role-thyroid-hormone-metabolic-homeostasis-1042.pdf
Kravchun, P., Lapshina, L., Zolotaykina, V. (2012). Dinamika urovney leykotriena S4, faktorov nespetsificheskogo vospaleniya, markerov oksidativnogo stressa, kardiogemodinamiki pri vklyuchenii vodorastvorimoy formyi kvertsetina v terapiyu ostroy serdechnoy nedostatochnosti [Dynamics of C4 leukotriene, factors of nonspecific inflammation, oxidative stress markers, cardiac hemodynamics when the water-soluble form of quercetin in the treatment of acute heart failure]. Scientific statements Belgorod State University. A series of "Medicine. Pharmacy", 4, 100–110.
Netjazhenko, V. Z., Mal'chevskaja, T. I., Mishanich, G. I. et al. (2010). Vybor metabolicheskoj terapii pri lechenii bol'nyh s ishemicheskoj bolezn'ju serdca. Novosti mediciny i farmacii, 7 (320), 8.
Schor, J. (2010). The influence of quercetin on exercise performance and muscle mitochondria. Natural Medicine Journal, 2 (5). Available at: http://www.naturalmedicinejournal.com/journal/2010-05/influence-quercetin-exercise-performance-and-muscle-mitochondria
Zaafan, M. A., Zaki, H. F., El-Brairy, A. I., Kenawy, S. A. (2013). Protective effects of atorvastatin and quercetin on isoprenaline-induced myocardial infarction in rats. Bulletin of Faculty of Pharmacy, Cairo University, 51 (1), 35–41. doi: 10.1016/j.bfopcu.2013.03.001
Kumar, S., Pandey, A. K. (2013). Chemistry and Biological Activities of Flavonoids: An Overview. The Scientific World Journal, 2013, 1–16. doi: 10.1155/2013/162750
Jeong, S.-M., Kang, M.-J., Choi, H.-N., Kim, J.-H., Kim, J.-I. (2012). Quercetin ameliorates hyperglycemia and dyslipidemia and improves antioxidant status in type 2 diabetic db/db mice. Nutrition Research and Practice, 6 (3), 201. doi: 10.4162/nrp.2012.6.3.201
Perez-Vizcaino, F., Duarte, J. (2010). Flavonols and cardiovascular disease. Molecular Aspects of Medicine, 31 (6), 478–494. doi: 10.1016/j.mam.2010.09.002
Gunduz, M., Gunduz, E., Kircelli, F., Okur, N., Ozkaya, M. (2012). Role of Surrogate Markers of Atherosclerosis in Clinical and Subclinical Thyroidism. International Journal of Endocrinology, 2012, 1–6. doi: 10.1155/2012/109797
Lee, J. H., Shin, Y.-J., Oh, J.-H., Lee, Y.-J. (2012). Pharmacokinetic interactions of clopidogrel with quercetin, telmisartan, and cyclosporine A in rats and dogs. Archives of Pharmacal Research, 35 (10), 1831–1837. doi: 10.1007/s12272-012-1017-7
Pavlyukovych, N., Trefanenko, I., Pavlyukovych, O. (2013). Bilkovyy ta lipidnyy spektr krovi pry poyednanomu perebihu ishemichnoyi khvoroby sertsya ta khronichnoho nekal'kul'oznoho kholetsystytu: terapevtychni mozhlyvosti kvertsetynu [Protein and lipid spectrum of the blood flow combined with coronary heart disease and chronic non-calculous cholecystitis: therapeutic possibilities quercetin]. Medical Journal of Bukovina, 17 (3), 172–176.
Gergerlioglu, H., Demir, E., Alp, M., Oz, M. (2015). Effects of quercetin in IL-6 and TNF-α levels in diabetic rats. The FASEB Journal, 29 (1).
Mahmoud, M. F., Hassan, N. A., El Bassossy, H. M., Fahmy, A. (2013). Quercetin Protects against Diabetes-Induced Exaggerated Vasoconstriction in Rats: Effect on Low Grade Inflammation. PLoS ONE, 8 (5), e63784. doi: 10.1371/journal.pone.0063784
Wang, L., Chen, J., Wang, B., Wu, D., Li, H., Lu, H. et. al (2014). Protective effect of quercetin on lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammatory cell influx. Experimental Biology and Medicine, 239 (12), 1653–1662. doi: 10.1177/1535370214537743
Téléchargements
Publié-e
Numéro
Rubrique
Licence
(c) Tous droits réservés Тетяна Вікторівна Олійник, Наталія Сергіївна Михайловська 2016
Cette œuvre est sous licence Creative Commons Attribution 4.0 International.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
